Lennox-Gastaut syndrome is a form of intractable epilepsy that is characterized by a high volume of seizures and develops early in life. Because the syndrome impairs intellectual development and limits information processing, many patients also display behavioral problems. Patients with Lennox-Gastaut syndrome may experience tonic, atonic, atypical absence, and myoclonic seizures. This form of epilepsy is often treatment resistant, and when patients do respond to a medication, they may develop a tolerance over time, but studies show that medical marijuana is effective at reducing intractable seizures.
Various scientific reviews note cannabis is a well-tolerated and effective medication at reducing or eliminating seizures. This is because CBD activates CB1 receptors, which dampens the release of neurotransmitters and reduces neuronal excitability. Controlled and double-blinded studies are currently underway, but in past questionnaires and surveys involving parents using cannabis to treat their children with epilepsy, 84% reported a reduction in their child's seizure frequency. Of those parents, 11% noted their children became completely seizure free and 42% reported a greater that 80% reduction in frequency. In addition, the children often became more alert, slept better, and were in better moods. Similarly, in a survey regarding children with Lennox-Gastaut syndrome being treated with high-CBD cannabis, 85% witnessed a reduction in seizure frequency and 14% became seizure free. These children also witnessed improvements in sleep, alertness, and mood.
This information has been brought to you by Medical Marijuana Inc. and approved by our Chief Medical Officer.